EVAXION BIOTECH A/S (EVAX) Stock Price, Quote, News and Overview
NASDAQ:EVAX - Nasdaq - US29970R2040 - ADR - Currency: USD
EVAX Quote, Performance and Key Statistics
EVAXION BIOTECH A/S
NASDAQ:EVAX (1/29/2025, 8:21:41 PM)
After market: 3.4992 +0.11 (+3.22%)3.39
-0.98 (-22.43%)
The current stock price of EVAX is 3.39 USD. In the past month the price decreased by -36.04%. In the past year, price decreased by -84.52%.
EVAX Latest News, Press Releases and Analysis
In today's session, these stocks are experiencing unusual volume.
Discover the stocks with unexpected trading volume in today's session on the US markets.
Friday's after hours session: top gainers and losers
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Top movers in Friday's session
Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
Top movers in Friday's session
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement
Following a constructive Nasdaq hearing panel on January 7, 2025, Evaxion has been granted a 180-day extension in relation to the Nasdaq minimum equity...
EVAX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.3 | 309.71B | ||
| AMGN | AMGEN INC | 14.66 | 151.41B | ||
| GILD | GILEAD SCIENCES INC | 21.58 | 119.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 865.73 | 113.70B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.13 | 75.52B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.15B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.34B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.20B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.14B | ||
| NTRA | NATERA INC | N/A | 22.21B | ||
| BIIB | BIOGEN INC | 8.84 | 21.04B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.37 | 16.64B |
Related stock screener links
About EVAX
Company Profile
Evaxion Biotech A/S engages in the discovery and development of immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Company Info
EVAXION BIOTECH A/S
Bredgade 34E, Copenhagen K
COPENHAGEN 1260 DK
CEO: Lars Staal Webner
Employees: 49
Company Website: https://www.evaxion-biotech.com/
EVAX FAQ
What is the stock price of EVAX?
The current stock price of EVAX is 3.39 USD.
What is the symbol for EVAXION BIOTECH A/S stock?
The exchange symbol of EVAXION BIOTECH A/S is EVAX and it is listed on the Nasdaq exchange.
On which exchange is EVAX stock listed?
EVAX stock is listed on the Nasdaq exchange.
Is EVAX a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for EVAX, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of EVAX.
Does EVAX stock pay dividends?
EVAX does not pay a dividend.
What is the Price/Earnings (PE) ratio of EVAX?
EVAX does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.46).
What is the Short Interest ratio of EVAX stock?
The outstanding short interest for EVAX is 22.36% of its float.
EVAX Technical Analysis
EVAX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to EVAX. EVAX may be in some trouble as it scores bad on both profitability and health.
EVAX Financial Highlights
Over the last trailing twelve months EVAX reported a non-GAAP Earnings per Share(EPS) of -1.46. The EPS decreased by 84.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -99.83% | ||
| ROE | -1213.49% | ||
| Debt/Equity | 7.99 |
EVAX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to EVAX. The Buy consensus is the average rating of analysts ratings from 9 analysts.